The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors.
 
Fangfei Gao
No Relationships to Disclose
 
Mary O'Brien
Employment - Takeda (I)
Honoraria - MSD; Pierre Fabre
Consulting or Advisory Role - MSD; Pierre Fabre
 
Debashis Sarker
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Blueprint Medicines; Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Novartis
 
Jaishree Bhosle
Honoraria - Pierre Fabre
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Roche
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pierre Fabre
 
Timothy Anthony Yap
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Janssen-Cilag; MSD Oncology
 
Martina Maria Uttenreuther-Fischer
Employment - Boehringer Ingelheim
 
Karine Pemberton
Employment - Boehringer Ingelheim
 
Rainer-Georg Goeldner
Employment - Boehringer Ingelheim
 
Sabrina Wiebe
Employment - Boehringer Ingelheim; Boehringer Ingelheim (I)
Patents, Royalties, Other Intellectual Property - Boehringer Ingelheim (Inst)
 
Johann de Bono
No Relationships to Disclose
 
Johann S. De Bono
No Relationships to Disclose
 
James F. Spicer
Honoraria - Boehringer Ingelheim; Lilly; Lytix Biopharma; Pierre Fabre; Roche; Shionogi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Shionogi
Research Funding - GlaxoSmithKline; Quintiles
Travel, Accommodations, Expenses - Boehringer Ingelheim; Merck